In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

A Phase III Failure Is Not Always Terminal But It Is Always Major

Bouncing Back From A Phase III Flop

Small Pharma’s Road To Recovery

Executive Summary

The passing of a decade always brings with it an inevitable glance in the rear-view mirror to see how far we have come. The pharma industry is no different and it would be remiss to ignore the failings of the industry’s collective R&D engine while also celebrating its successes.

You may also be interested in...



Deal Watch: Conatus Ends NASH Ambitions, Merges With Regenerative Medicine Firm Histogen

Reverse merger takes Histogen public as it seeks mid-stage data for male pattern baldness by end of 2020. AstraZeneca continues divestiture spree, sending five mature hypertension drugs to Atnahs.

Shield Therapeutics Looking At US Options For Feraccru

The UK biotech has revised its business strategy over the past year, and Shield's CEO believes the company's lead product for iron deficiency is now well positioned to compete with current and potential entrants in the therapeutic sector.

Can Fresh INTEREST Breathe New Life Into Faron's Traumakine?

Faron's ARDS drug looked doomed after the INTEREST study earlier this year but the Finnish group claims that a DNA analysis has identified some patients for whom Traumakine treatment could potentially be effective.

UsernamePublicRestriction

Register

LL006980

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel